Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis

Company Overview

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

Key Stats

• Today's Range: C$2.11 to C$2.18
• 50-Day Range: C$1.96 to C$2.73
• 52-Week Range: C$1.44 to C$3.16
• Volume: 19,005 shs
• Average Volume: 41,582 shs
• Market Capitalization: C$52.74 million
• P/E Ratio: 43.00
• Dividend Yield: N/A
• Price Target: C$5.25
• Consensus Rating: Buy

Medexus Pharmaceuticals Stock Analysis - MarketRank™

Medexus Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Medexus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Medexus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Medexus Pharmaceuticals is 43.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.33.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medexus Pharmaceuticals is 43.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 134.37.

Price to Book Value per Share Ratio

Medexus Pharmaceuticals has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MDP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medexus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Medexus Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for MDP.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: -0.20

News Sentiment

Medexus Pharmaceuticals has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Medexus Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for MDP on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Medexus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Medexus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$10,916.00 in company stock and sold C$0.00 in company stock.

Percentage Held by Insiders

Only 9.14% of the stock of Medexus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 8.32% of the stock of Medexus Pharmaceuticals is held by institutions.

MDP Stock Analysis - Frequently Asked Questions

How have MDP shares performed this year?

Medexus Pharmaceuticals' stock was trading at C$2.47 at the start of the year. Since then, MDP shares have decreased by 13.0% and is now trading at C$2.15.
View the best growth stocks for 2024 here.

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Medexus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS).

Company Calendar

• Today: 11/21/2024
• Next Earnings (Estimated): 2/05/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:MDP
• CUSIP: N/A
• CIK: N/A
• Web: www.medexus.com
• Phone: 877-633-3987
• Fax: N/A
• Employees: 98
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$5.25
• High Stock Price Target: C$8.25
• Low Stock Price Target: C$3.50
• Potential Upside/Downside: +144.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C$0.05
• Trailing P/E Ratio: 43.00
• Forward P/E Ratio: 13.16
• P/E Growth: N/A
• Net Income: C$1.09 million
• Net Margins: 1.00%
• Pretax Margin: N/A
• Return on Equity: 3.95%
• Return on Assets: 4.89%

Debt

• Debt-to-Equity Ratio: 143.72
• Current Ratio: 1.11
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$108.78 million
• Price / Sales: 0.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$1.33 per share
• Price / Book: 1.62

Miscellaneous

• Outstanding Shares: 24,530,000
• Free Float: N/A
• Market Cap: C$52.74 million
• Optionable: Not Optionable
• Beta: 1.96